Dr. Karim Richard Masri, a Rheumatologist at the Bon Secours Rheumatology center in Richmond, VA discusses new data released by Horizon Therapeutics at the Annual European Congress of Rheumatology (EULAR 2020) that shows the benefit of combining immunomodulators with KRYSTEXXA® (pegloticase injection) to help more people with uncontrolled gout achieve complete and durable responses. Other data shared at EULAR addressed the rate of amputation reinforcing the systemic and potentially devastating impact of uncontrolled gout. Dr. Masri also discusses details for prescribers on how to ensure patients are supported during COVID-19.
Dr. Karim Richard Masri is a Rheumatologist at the Bon Secours Rheumatology Center in Richmond, Virginia. He attended the University of Houston – Downtown for his undergraduate degree, received his medical degree from the American University of Beirut, and completed his internal medicine internship and residency at the University of Kansas School of Medicine – Wichita. Dr. Masri also completed a rheumatology fellowship at Johns Hopkins University School of Medicine. Dr. Masri is board certified by the American Board of Internal Medicine in Internal Medicine and Rheumatology. He is certified by the American College of Rheumatology in musculoskeletal ultrasound (RhMSUS) and uses musculoskeletal ultrasound in the diagnostic and therapeutic management of inflammatory arthritis. His interests in rheumatology include SLE, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, gout/pseudogout, vasculitis, scleroderma, and myositis. He is a cyclist and snowboarder. Look him up on Strava.